StockNews.com Begins Coverage on Advaxis (OTCMKTS:ADXS)
StockNews.com Begins Coverage on Advaxis (OTCMKTS:ADXS)
StockNews.com assumed coverage on shares of Advaxis (OTCMKTS:ADXS – Get Rating) in a report published on Monday. The firm issued a sell rating on the biotechnology company's stock.
Advaxis Price Performance
Shares of Advaxis stock opened at $1.79 on Monday. The firm has a market cap of $3.25 million, a price-to-earnings ratio of -0.20 and a beta of 2.44. Advaxis has a 52-week low of $1.00 and a 52-week high of $11.18. The stock has a 50-day simple moving average of $1.73 and a 200-day simple moving average of $1.68.
Get Advaxis alerts:Advaxis Company Profile
(Get Rating)
Advaxis, Inc is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins. The firm has four franchises in various stages of clinical and pre-clinical development, namely: HPV-associated cancers, prostate cancer, neoantigen therapy and hotspot mutation therapy.
Read More
- Get a free copy of the StockNews.com research report on Advaxis (ADXS)
- META Platforms May See its Biggest Opening Yet for New Highs
- Penny Stock Vinco Ventures Could Be Big Winner
- Is Chip Design Specialist Synopsys A Gem Hiding In Plain Sight?
- Should You Park Some Capital with Casey's General Stores?
- Crowdstrike Stock: While The Iron Is Hot!
Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.
StockNews.com承担了对以下股票的报道Advaxis(OTCMKTS:ADXS-获取评级)在周一发布的一份报告中。该公司对这家生物技术公司的股票发布了卖出评级。
Advaxis性价比
Advaxis的股票周一开盘报1.79美元。该公司的市值为325万美元,市盈率为-0.20倍,贝塔系数为2.44。Advaxis的52周低点为1.00美元,52周高位为11.18美元。该股的50日简单移动均线切入位在1.73美元,200日简单移动均线切入位在1.68美元。
到达前进轴警报:Advaxis公司简介
(获取评级)
Advaxis,Inc.是一家生物技术公司,从事癌症免疫疗法的发现、开发和商业化。它管理的平台技术利用减毒活的单核细胞增生性李斯特菌生物工程来分泌抗原或佐剂融合蛋白。该公司在临床和临床前开发的不同阶段拥有四个专营权,即:HPV相关癌症、前列腺癌、新抗原治疗和热点突变治疗。
阅读更多内容
- 免费获取StockNews.com关于Advaxis的研究报告(ADXS)
- Meta平台可能迎来迄今最大的开盘创新高
- Penny Stock Vinco Ventures可能成为大赢家
- 芯片设计专家Synopsys是隐藏在众目睽睽之下的宝石吗?
- 你应该在凯西的百货商店里预留一些资本吗?
- CrowdStrike股票:趁热打铁!
接受Advaxis Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Advaxis和相关公司的最新新闻和分析师评级的每日简要摘要。
译文内容由第三方软件翻译。
风险及免责提示
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧